

About True-ViP-2
Vitiligo is a chronic autoimmune skin condition that causes patches of skin to lose their pigment, resulting in areas of lighter skin. Although the condition is not physically harmful, it can have a significant impact on self-esteem, emotional wellbeing, and quality of life, particularly in children and young people. Effective treatment options for younger children remain limited, creating a need for further research into safe and targeted therapies. The TRuE-ViP-2 study is a clinical trial evaluating the safety and efficacy of topical ruxolitinib cream in children with non-segmental vitiligo. Through regular clinical assessments and long-term follow-up, the study aims to determine how effectively ruxolitinib can restore skin pigmentation while monitoring its safety and tolerability in a paediatric population. Findings from the study may help expand treatment options for children with vitiligo and support the development of evidence-based approaches to managing this condition.
Study details

Condition
Vitiligo

Drug
Ruxolitinib

Age range
6-11

Funder
Incyte Corporation